poisar

Stocks · News reference

Arcus Biosciences shares are trading higher after HC Wainwright & Co. maintained its Buy rating on the stock and raised its price target from $32 to $45.

Jul 20, 2026, 2:35 PMBenzinga Newsdesk
Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

RCUS
Source
benzinga
Observed
Jul 20, 2026, 2:35 PM
Checked
Jul 20, 2026, 2:35 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  4. Jul 22, 2026, 8:48 PMBenzinga Newsdesk

    Arcus Biosciences Announces A Clinical Supply Agreement With AVEO Oncology To Evaluate Casdatifan; Agreement Supports A New Randomized Cohort Within The ARC-20 Study Evaluating Investigational Casdatifan Plus Tivozanib Versus Tivozanib Alone In Patients Who Received Prior HIF-2α-inhibitor Therapy; Enrollment Expected To Begin In Q4 2026

    This agreement supports a new randomized cohort within the ARC-20 study evaluating investigational casdatifan plus tivozanib versus tivozanib alone in patients who received prior HIF-2α-inhibitor therapyEnrollment is

    Read original at benzinga
    RCUS